Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation
Real world results of liquid biopsy in early-stage solid tumors
Real world results of liquid biopsy in stage 4 solid tumors and potential “clinical actionability”
Cancer patient paired congruence between a commercially available tumor tissue and a liquid biopsy NGS assays
Blood-Drop Liquid Biopsy for Monitoring Mutation Load and Therapeutic Responses
Cancer Therapy & Oncology International Journal, Case Report in Volume 1 Issue 5 – June 2016
Circulating cell-free DNA: The future of personalized medicine in ovarian cancer management
American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, IL., Published June 4, 2016
AACR 2016 Research Shows CIRCULOGENE Liquid Biopsy Excels at Real-Time Monitoring of Cancer Mutations
American Association of Cancer Research (AACR) 2016 Annual Meeting in New Orleans., Published April 14, 2016
Circulating Cell-Free DNA:
The Blood Biopsy in Cancer Management
MOJ Cell Science & Report, Published March 25, 2015
Next-Generation Targeted Sequencing of Circulating Cell-Free DNA from Droplet Volumes of Blood
International Journal of Life Sciences Research
Vol. 3, Issue 3, pp: (23-29), Month: July – September 2015
Next-Generation Liquid Biopsy: Tumor Monitoring from Droplet Volumes of Blood
Journal of Cancer Prevention & Current Research, Vol. 3 Issue 1 2015, Published July 23, 2015
Next-generation sequencing analysis of high-quality and high-quantity cell-free circulating DNA prepared from droplet volumes of patient plasma.
2015 ASCO Annual Meeting, Citation: J Clin Oncol 33, 2015 (suppl; abstr e22008)
Next-Generation Sequencing and Targeted Cancer Therapy
MOJ Cell Science & Report, Published: July 27, 2015